aggressive discount were withdrew in Jan-Feb while demand from lockdown only emerged in the last week of March. APRU continued declining as the competition remained elevated particularly with deep discount
aggressive discount were withdrew in Jan-Feb while demand from lockdown only emerged in the last week of March. APRU continued declining as the competition remained elevated particularly with deep discount
, Depreciation and Amortization (EBITDA) was THB 84 million, declining by THB 50million. In 9M18, the Company reported total revenue of THB 3,943million, an increase of 4.4% yoy, mainly from an increase in revenue
of Bt1,330mn, growing 7.1% YoY from unique proposition of vertical solutions in collaboration with partnerships and efforts to expand the digital ecosystem to support the digital operations of
) attributable to Equity holders of the Company 232 333 (100) -30% Earnings per share (THB/share) 0.39 0.55 (0.16) -29% 2 / 3 Consolidated financial results of 12-month ended period ● Declining in sales revenue of
million in 3Q17 and 9M17, respectively. The main drivers were attributable to a decrease in room revenue due to three hotel renovations and an increase in administrative expenses to support business
administrative expense to support business expansion. Without the non-recurring profit related to sale of Dusit Princess Korat, core EBITDA was THB 806 million, a 12.3% decrease from 2016. The Company reported net
monitor the situation closely while continuing to focus on providing support to customers and at the same time monitoring the status of customers still under financial assistance initiated during 2020
encouraged customer’s spending through AEON credit cards. The Company launched a special campaign “AEON 25 th Years Anniversary 25 Cars” to celebrate our success and thanks to all customers for their support
guidelines for employees to curtail the spread of COVID-19 as well as support our partner and community to help prevent the spread of the virus and support those already affected. Throughout the COVID-19